Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Long-term data on R-CHOP in follicular lymphoma

Wantanabe T et al. Lancet Haematol. 2018 Nov;5(11):e520-31

Key clinical point: Long-term data shows that R-CHOP is effective and safe as first-line treatment of patients with follicular lymphoma.

Major finding: Approximately one-third of patients treated with R-CHOP-14 plus G-CSF or R-CHOP-21 had no disease progression after 10 years of follow-up.

Study details: Long-term analysis of a randomized phase 2/3 trial in 299 patients with indolent B-cell lymphomas, including follicular lymphoma.

Disclosures: The study was supported by the Ministry of Health, Labor and Welfare of Japan and by the National Cancer Center Research and Development Fund of Japan. Dr. Wantanabe has received honoraria from Bristol-Myers Squibb, Takeda, Taisho Toyama, Celgene, Nippon Shinyaku, and Novartis and funding resources from TakaraBio and United Immunity to support the Department of Immuno-Gene Therapy in Mie University. Multiple coauthors reported similar relationships.

Read the article here.


Wantanabe T et al. Lancet Haematol. 2018 Nov;5(11):e520-31.